ALT Share Price Performance
US$3.35
-0.32 (-8.72%)
80.5% undervalued intrinsic discount
US$17.22
Fair Value
Price US$3.35
AnalystConsensusTarget US$17.22
AnalystHighTarget US$28.00
Fair ValueUS$17.22
Share Pricen/a
Altimmune, Inc. Stock Price
- 2 Narratives written by author
- 0 Comments on narratives written by author
- 46 Fair Values set on narratives written by author
ALT Community Narratives
AN
Fair Value
·Fair Value US$17.22 80.5% undervalued intrinsic discount
Dual Agonist Liver Disease Advances Will Drive A Future Multi Indication Metabolic Franchise
0users have liked this narrative
0users have commented on this narrative
5users have followed this narrative
AN
Fair Value
·Fair Value US$28 88.0% undervalued intrinsic discount
Noninvasive Testing And MASH Breakthroughs Will Unlock Major Long Term upside
1users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
Altimmune
80.5% undervalued intrinsic discount
Dual Agonist Liver Disease Advances Will Drive A Future Multi Indication Metabolic Franchise
View narrativeAN
Updated 29 Jul
Altimmune
88.0% undervalued intrinsic discount
Noninvasive Testing And MASH Breakthroughs Will Unlock Major Long Term upside
View narrativeAN
Published 20 Dec 2025
Trending Discussion
No trending discussion available.
Recently Updated Narratives
AN
ALT: MASH And Alcohol Use Disorder Data Will Drive Future Upside
Fair Value: US$17.22 80.5% undervalued intrinsic discount
5 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Noninvasive Testing And MASH Breakthroughs Will Unlock Major Long Term upside
Fair Value: US$28 88.0% undervalued intrinsic discount
2 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Altimmune, Inc. Key Details
Last Reported Earnings
Jun 30, 2026
Next Reporting Earnings
n/a
- -0.47
- -215,138.71%
- -296,000.00%
- 7.3%
About ALT
- Founded
- 1997
- Employees
- 57
- CEO
- WebsiteView website
Altimmune, Inc., a late clinical stage biopharmaceutical company, focuses on developing novel therapies for serious liver diseases. Its lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist, which is in Phase 3 clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis, alcohol use disorder, and alcohol-associated liver disease. The company was founded in 1997 and is headquartered in Gaithersburg, Maryland.
